Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 271

1.

PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.

Ginsberg C, Craven TE, Chonchol MB, Cheung AK, Sarnak MJ, Ambrosius WT, Killeen AA, Raphael KL, Bhatt UY, Chen J, Chertow GM, Freedman BI, Oparil S, Papademetriou V, Wall BM, Wright CB, Ix JH, Shlipak MG; SPRINT Research Group.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1816-1824. doi: 10.2215/CJN.05390518. Epub 2018 Nov 13.

PMID:
30425104
2.

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25.

PMID:
30361335
3.

Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?

Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Riessen E, Shapiro B, Stergiou GS, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V.

J Clin Hypertens (Greenwich). 2018 Nov;20(11):1644-1645. doi: 10.1111/jch.13395. Epub 2018 Oct 17. No abstract available.

4.

Role of PCSK9 inhibitors in high risk patients with dyslipidemia: Focus on familial hypercholesterolemia.

Papademetriou V, Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Dimitriadis K, Tsioufis K.

Curr Pharm Des. 2018 Oct 10. doi: 10.2174/1381612824666181010124657. [Epub ahead of print]

PMID:
30317985
5.

Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis.

Kataoka Y, Delacroix S, Sidharta S, Andrews J, Nicholls SJ, Tsioufis CP, Papademetriou V, Worthley SG.

Int J Nephrol Renovasc Dis. 2018 Sep 27;11:259-266. doi: 10.2147/IJNRD.S161313. eCollection 2018.

6.

Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study.

Papademetriou V, Tsioufis C, Chung A, Geladari C, Andreadis EA.

J Clin Hypertens (Greenwich). 2018 Oct;20(10):1411-1416. doi: 10.1111/jch.13371. Epub 2018 Oct 1.

7.

The Reply.

Papademetriou V.

Am J Med. 2018 Jul;131(7):e317. doi: 10.1016/j.amjmed.2018.01.051. No abstract available.

PMID:
29909847
8.

The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread".

Sanidas E, Papadopoulos DP, Velliou M, Tsioufis K, Mantzourani M, Iliopoulos D, Perrea D, Barbetseas J, Papademetriou V.

Am J Hypertens. 2018 Aug 3;31(9):961-969. doi: 10.1093/ajh/hpy087.

PMID:
29788148
9.
10.

Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study.

Kasiakogias A, Tsioufis C, Dimitriadis K, Konstantinidis D, Koumelli A, Leontsinis I, Andrikou E, Vogiatzakis N, Marinaki S, Petras D, Fragoulis C, Konstantinou K, Papademetriou V, Tousoulis D.

J Hum Hypertens. 2018 Jul;32(7):487-493. doi: 10.1038/s41371-018-0065-y. Epub 2018 May 1.

PMID:
29713047
11.

Attended and Unattended Automated Office Blood Pressure Measurements Have Better Agreement With Ambulatory Monitoring Than Conventional Office Readings.

Andreadis EA, Geladari CV, Angelopoulos ET, Savva FS, Georgantoni AI, Papademetriou V.

J Am Heart Assoc. 2018 Apr 7;7(8). pii: e008994. doi: 10.1161/JAHA.118.008994.

12.

Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.

Papademetriou V, Geladari E.

Cardiovasc Hematol Disord Drug Targets. 2018;18(2):127-133. doi: 10.2174/1871529X18666180405102658.

PMID:
29618313
13.

Is statin therapy safe and effective in patients with chronic Kidney disease?

Raman VK, Geladari E, Papademetriou V.

Curr Pharm Des. 2018 Jan 9. doi: 10.2174/1381612824666180110100103. [Epub ahead of print]

PMID:
29318962
14.

Human Immunodeficiency Virus Infection And Hypertension. Is There a Connection?

Sanidas E, Papadopoulos DP, Velliou M, Tsioufis K, Barbetseas J, Papademetriou V.

Am J Hypertens. 2018 Mar 10;31(4):389-393. doi: 10.1093/ajh/hpx208.

PMID:
29220484
15.

From 'essential' hypertension to intensive blood pressure lowering: the pros and cons of lower target values.

L├╝scher TF, Kjeldsen SE, Mancia G, Papademetriou V.

Eur Heart J. 2017 Nov 21;38(44):3258-3271. doi: 10.1093/eurheartj/ehx643. No abstract available.

PMID:
29177419
16.
17.

Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension.

Doumas M, Tsioufis C, Fletcher R, Amdur R, Faselis C, Papademetriou V.

J Am Heart Assoc. 2017 Nov 3;6(11). pii: e007131. doi: 10.1161/JAHA.117.007131.

18.

SPYRAL HTN-OFF MED study: Renal denervation in the spiral orbits of current results and future studies.

Tsioufis C, Dimitriadis K, Papademetriou V, Tousoulis D.

Hellenic J Cardiol. 2017 Sep - Oct;58(5):320-321. doi: 10.1016/j.hjc.2017.09.012. Epub 2017 Oct 19. No abstract available.

19.

Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.

Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK; SPRINT Research Group.

Circulation. 2018 Jan 9;137(2):134-143. doi: 10.1161/CIRCULATIONAHA.117.030848. Epub 2017 Oct 11.

PMID:
29021322
20.

Air pollution and arterial hypertension. A new risk factor is in the air.

Sanidas E, Papadopoulos DP, Grassos H, Velliou M, Tsioufis K, Barbetseas J, Papademetriou V.

J Am Soc Hypertens. 2017 Nov;11(11):709-715. doi: 10.1016/j.jash.2017.09.008. Epub 2017 Sep 27. Review.

PMID:
28989071

Supplemental Content

Loading ...
Support Center